R21/Matrix-M is the second licensed malaria vaccine. It was developed by Oxford University and licensed to the Serum Institute of India (SIIPL). The WHO prequalified the R21/Matrix-M malaria vaccine in December 2023 after Phase II trial results showed 77% efficacy against clinical malaria in Burkina Faso (seasonal malaria transmission) and Phase III trial results showed 75% and 68% efficacy against clinical malaria at the seasonal sites and standard sites, respectively.